AVDL

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.22
Percentage change -2.07	%

Peers: JAZZ NBIX BMRN SUPN XENE AXSM VYGR PRTA KNSA NERV

| Held by: VTI IWM IWO VTWO VTWG ESML NUSC RSSL FYX FYC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.77	Insider Own	8.52%	Shs Outstand	96.34M	Perf Week	3.90%
Market Cap	1.00B	Forward P/E	21.55	EPS next Y	0.48	Insider Trans	0.47%	Shs Float	88.15M	Perf Month	-13.56%
Income	-72.58M	PEG	-	EPS next Q	-0.03	Inst Own	74.83%	Short Float	11.10%	Perf Quarter	-24.76%
Sales	138.16M	P/S	7.25	EPS this Y	75.72%	Inst Trans	0.85%	Short Ratio	8.26	Perf Half Y	-34.28%
Book/sh	0.78	P/B	13.41	EPS next Y	199.31%	ROA	-40.17%	Short Interest	9.79M	Perf Year	-27.49%
Cash/sh	0.68	P/C	15.21	EPS next 5Y	15.00%	ROE	-78.54%	52W Range	9.41 - 19.09	Perf YTD	-26.42%
Dividend Est.	-	P/FCF	-	EPS past 5Y	4.78%	ROI	-65.79%	52W High	-45.57%	Beta	1.31
Dividend TTM	-	Quick Ratio	2.60	Sales past 5Y	-40.99%	Gross Margin	93.38%	52W Low	10.41%	ATR (14)	0.68
Dividend Ex-Date	-	Current Ratio	2.97	EPS Y/Y TTM	64.19%	Oper. Margin	-46.33%	RSI (14)	39.80	Volatility	4.56% 5.80%
Employees	154	Debt/Eq	0.49	Sales Y/Y TTM	1523.50%	Profit Margin	-52.53%	Recom	1.00	Target Price	23.64
Option/Short	Yes / Yes	LT Debt/Eq	0.48	EPS Q/Q	93.27%	Payout	-	Rel Volume	0.91	Prev Close	10.61
Sales Surprise	3.28%	EPS Surprise	63.28%	Sales Q/Q	613.22%	Earnings	Nov 12 BMO	Avg Volume	1.18M	Price	10.39
SMA20	-2.86%	SMA50	-16.64%	SMA200	-30.44%	Trades		Volume	1,077,166	Change	-2.07%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-12-24	Initiated	Rodman & Renshaw	Buy	$27
Mar-05-24	Reiterated	Oppenheimer	Outperform	$27 → $29
Mar-05-24	Reiterated	Needham	Buy	$20 → $22
Mar-05-24	Reiterated	H.C. Wainwright	Buy	$21 → $25
Feb-06-24	Initiated	UBS	Buy	$21
Nov-30-22	Upgrade	Jefferies	Hold → Buy	$6.50 → $11
Aug-10-22	Downgrade	Jefferies	Buy → Hold	$6 → $8
Jul-28-22	Resumed	Craig Hallum	Buy	$15.50 → $12
May-26-22	Downgrade	Stifel	Buy → Hold	$9 → $2
Sep-23-21	Initiated	Needham	Buy	$17
Jul-31-20	Initiated	Oppenheimer	Outperform	$19
Jul-21-20	Initiated	SVB Leerink	Outperform	$17
Jun-30-20	Initiated	H.C. Wainwright	Buy	$15
Apr-03-20	Initiated	Jefferies	Buy	$14
Mar-12-20	Initiated	Stifel	Buy	$14
Feb-26-20	Initiated	Piper Sandler	Overweight	$14
Jan-30-20	Initiated	Craig Hallum	Buy	$15
Jun-14-19	Upgrade	Ladenburg Thalmann	Neutral → Buy	$6
Feb-08-19	Downgrade	Ladenburg Thalmann	Buy → Neutral

Show Previous Ratings

Dec-11-24 08:00AM	Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy (GlobeNewswire)
Nov-13-24 08:00AM	Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference (GlobeNewswire) -8.59%
02:09AM	Avadel Pharmaceuticals PLC (AVDL) Q3 2024 Earnings Call Highlights: Strong Patient Growth and ... (GuruFocus.com)
Nov-12-24 07:21AM	Avadel: Q3 Earnings Snapshot (Associated Press Finance) -19.33%
07:00AM	Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
07:10AM	Loading…
Nov-11-24 07:10AM	Avadel Pharmaceuticals PLC (AVDL) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-04-24 08:00AM	Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12 (GlobeNewswire)
Nov-01-24 11:41AM	US court upholds Avadels narcolepsy drug approval amid exclusivity battle (Pharmaceutical Technology)
Oct-31-24 07:00AM	Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation (GlobeNewswire) +19.83%
Oct-24-24 08:00AM	Avadel Pharmaceuticals and nference Announce Publication of Real-World Data in Sleep Advances (GlobeNewswire)
Oct-18-24 04:34PM	Avadel wins FDA approval for narcolepsy drug Lumryz in children (Pharmaceutical Technology)
Oct-17-24 09:41AM	Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy (GlobeNewswire) +5.14%
Oct-09-24 05:36PM	Avadel Pharmaceuticals PLC (AVDL) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Sep-25-24 08:00AM	Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ (sodium oxybate) Extended-Release Oral Suspension in Improving Narcolepsy Symptoms Regardless of Concomitant Use of an Alerting Agent (GlobeNewswire)
Sep-03-24 08:00AM	Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII) (GlobeNewswire)
08:00AM	Loading…
Aug-28-24 08:00AM	Avadel Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire) -5.95%
Aug-27-24 08:46PM	Avadel Pharmaceuticals plc (AVDL): One of Oppenheimer's Top Stock Picks For the Next 12 Months (Insider Monkey)
Aug-20-24 08:00AM	Avadel Pharmaceuticals Announces Publication in Clinical Therapeutics of Data Highlighting Weight Loss in People with Narcolepsy Treated with LUMRYZ (sodium oxybate) Extended-Release Oral Suspension (GlobeNewswire)
Aug-08-24 07:13AM	Avadel: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-06-24 04:06PM	Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82 (Investor's Business Daily)
Aug-05-24 09:55AM	Does Avadel (AVDL) Have the Potential to Rally 43.6% as Wall Street Analysts Expect? (Zacks)
Aug-01-24 08:00AM	Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2024 Financial Results on August 8 (GlobeNewswire)
06:32AM	Avadel announces first subject dosing in Phase III idiopathic hypersomnia trial (Clinical Trials Arena)
Jul-31-24 04:05PM	Avadel Pharmaceuticals Announces First Patient Dosed in Phase 3 REVITALYZ Trial of LUMRYZ (sodium oxybate) Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia (GlobeNewswire)
Jun-27-24 04:05PM	Avadel Pharmaceuticals to Join Russell 3000 Index (GlobeNewswire)
May-30-24 08:00AM	Avadel Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
May-22-24 08:00AM	Avadel Pharmaceuticals Shares New LUMRYZ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024 (GlobeNewswire)
May-21-24 07:00AM	Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors (GlobeNewswire)
May-09-24 03:36PM	Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:55AM	Loading…
May-08-24 11:55AM	AVDL Stock Earnings: Avadel Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace) -10.62%
09:36AM	Avadel Pharmaceuticals Q1 Loss Narrows (MT Newswires)
08:36AM	Avadel Pharmaceuticals Reports First Quarter 2024 Earnings: Revenue Surpasses Estimates but Net ... (GuruFocus.com)
07:17AM	Avadel: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-01-24 08:00AM	Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8 (GlobeNewswire)
Apr-29-24 09:55AM	Wall Street Analysts Predict a 28.58% Upside in Avadel (AVDL): Here's What You Should Know (Zacks)
Apr-21-24 10:39AM	11 Best Low Price Pharma Stocks To Invest In (Insider Monkey)
Apr-01-24 08:00AM	Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference (GlobeNewswire)
Mar-05-24 10:25AM	Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:00AM	Avadel Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-04-24 03:37PM	Avadel Pharmaceuticals Issues Statement On Patent Litigation (GlobeNewswire) +17.57%
06:30AM	Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-26-24 08:00AM	Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 4 (GlobeNewswire)
Feb-07-24 08:00AM	Avadel Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-18-24 10:35AM	Here's Why You Should Invest in Avadel (AVDL) Stock Now (Zacks)
Jan-15-24 12:00PM	Avadel (AVDL) is a Great Momentum Stock: Should You Buy? (Zacks)
09:55AM	How Much Upside is Left in Avadel (AVDL)? Wall Street Analysts Think 37.36% (Zacks)
Jan-12-24 08:32AM	Why Avadel Pharmaceuticals (AVDL) Stock Might be a Great Pick (Zacks)
Jan-08-24 07:00AM	Avadel Pharmaceuticals Announces Strong LUMRYZ Launch Performance and Provides Preliminary Fourth Quarter and Full Year 2023 Financial Highlights (GlobeNewswire) +8.42%
Nov-10-23 12:16PM	Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 07:07AM	Avadel: Q3 Earnings Snapshot (Associated Press Finance) +11.90%
07:00AM	Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-07-23 08:00AM	Avadel Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-30-23 08:00AM	Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 8 (GlobeNewswire)
Oct-20-23 08:00AM	Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ (sodium oxybate) for extended-release oral suspension (CIII) at World Sleep 2023 (GlobeNewswire)
Oct-05-23 08:00AM	Avadel Pharmaceuticals to Present at the Jefferies Biotech CNS/Neuro Summit (GlobeNewswire) +7.88%
Sep-26-23 11:52AM	Avadel Pharmaceuticals PLC (AVDL): Is It Really Priced Right? An In-depth Exploration (GuruFocus.com)
Aug-31-23 10:16PM	12 Best High Risk High Reward Stocks To Buy Now (Insider Monkey)
08:00AM	Avadel Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-13-23 08:09AM	Geoffrey Glass Bought 13% More Shares In Avadel Pharmaceuticals (Simply Wall St.)
Aug-11-23 08:28AM	Investing in Avadel Pharmaceuticals (NASDAQ:AVDL) five years ago would have delivered you a 182% gain (Simply Wall St.) +8.34%
07:01AM	Daily Vickers Top Buyers & Sellers for 08/11/2023 (Argus Research)
Aug-10-23 10:32PM	JANUS HENDERSON GROUP PLC Increases Stake in Avadel Pharmaceuticals PLC (GuruFocus.com)
Aug-09-23 07:07AM	Avadel: Q2 Earnings Snapshot (AP Finance)
07:00AM	Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 04:05PM	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-02-23 08:00AM	Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9 (GlobeNewswire)
Jul-28-23 02:56PM	10 Best Small Cap Pharma Stocks to Buy (Insider Monkey)
Jul-20-23 04:05PM	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-06-23 04:05PM	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-03-23 04:50PM	Analysts Are Increasing Price Targets of These 10 Stocks (Insider Monkey) -8.28%
Jun-23-23 09:57AM	Jazz Pharmaceuticals Sues FDA Over Approval Of Rival Product, Calls It 'Unlawful' (Benzinga) -11.41%
Jun-22-23 08:00AM	Avadel Pharmaceuticals to Host Commercial Day on June 29 for LUMRYZ (sodium oxybate) extended release for oral solution, CIII (GlobeNewswire) +6.12%
Jun-20-23 10:10AM	Avadel Pharmaceuticals' Charts Are Pointed Higher (TheStreet.com)
Jun-14-23 08:00AM	Avadel Pharmaceuticals Sponsors the Academy of Sleep Medicine Foundations 2023 Young Investigators Research Forum (GlobeNewswire)
Jun-13-23 08:00AM	Avadel Pharmaceuticals Announces Publication of Study Data in Advances in Therapy Highlighting Need for Once-at-Bedtime Oxybate Dosing for Narcolepsy (GlobeNewswire)
Jun-06-23 04:05PM	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-05-23 07:00AM	Avadel Pharmaceuticals Announces U.S. Commercial Launch of LUMRYZ (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Adults Living with Narcolepsy (GlobeNewswire)
Jun-01-23 08:00AM	Avadel Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-31-23 04:00PM	Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ at SLEEP 2023 (GlobeNewswire)
May-21-23 08:20AM	Independent Director of Avadel Pharmaceuticals Picks Up 8.4% More Stock \ (Simply Wall St.)
May-05-23 03:44PM	Why Shares of Avadel Soared This Week (Motley Fool)
May-04-23 06:14PM	Avadel: Q1 Earnings Snapshot (AP Finance)
04:05PM	Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-03-23 04:05PM	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.53%
07:24AM	Avadel Pharmaceuticals plc (NASDAQ:AVDL) Shares Could Be 45% Below Their Intrinsic Value Estimate (Simply Wall St.)
May-01-23 01:20PM	Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy (GlobeNewswire) +11.93%
Apr-20-23 04:05PM	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.78%
Apr-10-23 08:00AM	Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference (GlobeNewswire) +7.23%
Apr-05-23 07:44PM	Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q4 2022 Earnings Call Transcript (Insider Monkey)
Apr-03-23 04:05PM	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.24% -8.61%
Mar-30-23 07:00AM	Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-29-23 09:27PM	Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30 (GlobeNewswire)
09:24PM	Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred Shares (GlobeNewswire)
04:13PM	Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering of ADSs and Series B Preferred Shares (GlobeNewswire)
04:01PM	Avadel Pharmaceuticals Enters into Royalty Agreement with RTW Investments for up to $75 Million (GlobeNewswire)
Mar-22-23 07:00AM	Avadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ Ahead of Anticipated Final Approval Decision (GlobeNewswire) +7.85%
Mar-21-23 04:05PM	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-02-23 07:00AM	Avadel Pharmaceuticals Requests Final FDA Approval for LUMRYZ (sodium oxybate) extended-release oral suspension (GlobeNewswire)

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MCHUGH THOMAS S	Chief Financial Officer	Dec 11 '24	Buy	10.49	5,000	52,432	85,500	Dec 12 07:00 AM
Divis Gregory J	Chief Executive Officer	Dec 06 '24	Buy	9.98	9,598	95,759	9,598	Dec 10 06:14 PM
Divis Gregory J	Chief Executive Officer	Dec 09 '24	Buy	9.82	402	3,948	10,000	Dec 10 06:14 PM
Glass Geoffrey Michael	Director	Dec 10 '24	Buy	9.84	20,279	199,641	75,904	Dec 10 06:13 PM
Palczuk Linda	Director	Dec 06 '24	Buy	10.19	3,000	30,568	66,400	Dec 10 07:00 AM
MCHUGH THOMAS S	Chief Financial Officer	Jan 16 '24	Buy	14.50	2,000	29,000	80,500	Jan 16 04:36 PM
McCamish Mark Anthony	Director	Dec 28 '23	Sale	14.53	75,000	1,089,750	67,025	Dec 29 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Avadel Pharmaceuticals plc

Upgrade your FINVIZ experience